Skip to content

SILENCE CANCER

Our primary objective is to provide an affordable mRNA cancer treatment that rapidly induces cancer cell death with negligible side effects.

We plan to offer KOP'S cancer treatment drug through intravenous push administration, at your nearby health practitioner's office.

Our aim is to make available a cost-effective and efficient mRNA cancer treatment accessible to anyone suffering from cancer.

KOP THERAPEUTICS EXPANDS CANCER RESEARCH IN CANADA

KOP moves to animal studies in Canada in collaboration with the BC Cancer Institute / BC Cancer Experimental Therapeutics

OUR COMPANY

Introduction

KOP Therapeutics is a Canadian preclinical biotechnology company, headquartered in Montreal, Quebec focused on the discovery and development of a novel RNA-based cancer therapy platform. The company partners with leading research institutions and contracts research organizations to advance its proprietary messenger gene platform, aiming to target and destroy cancer cells with no observed toxicity to date. KOP continues its cancer research and commercialization of its newly discovered KOP Genomic Drug Platform, a cell-based Antisense Oligonucleotide (AON) Cancer Therapy in Canada.

SCIENCE

Targeted Oncogene Silencing Technology

KOP is focused on the development / validation of its newly discovered Targeted Genomic Messenger Drug involving a cell-based Antisense Oligonucleotide (AON) Cancer Therapy. The therapy is designed to “silence” the cancer gene, critical to cancer cell nourishment, resulting in cancer cell death with negligible side effects. In Vitro, KOP has validated the drug in prostate, breast, brain and ovarian cancer cells, and PC3 Cancer cells in-vivo. Specifically, in-vivo “KOP-101” has shown tumor reduction, tumor inhibition in male nude mice with Prostate cancer tumors. There was no observed toxicity as a result of the study.

Targeted and Low Toxicity Gene Silencing for Prostate Cancer

A crucial and key advantage of KOP’s Technology Platform is the targeted and low toxicity approach, which is crucial for minimizing side effects and improving patient outcomes. The ability to silence a previously unrecognized gene on cancer cells while avoiding significant harm to healthy cells is a major breakthrough, particularly for cancers such as prostate cancer where targeted therapies are highly sought after.

FIND OUT MORE

Team

Principal Investigators
KOP Scientific Advisory Board

Aligned with Leading Experts in Emerging Cancer Treatment

KOP is led by Drs. Thakur and Wickstrom, they have been working together for over two decades on cancer gene activity, imaging and therapy. Collectively, they have published 700+ peer-reviewed papers, various patents, and 6 books relating to molecular design, nucleic acid structure, gene function, mRNA translation, protein structure, and cell biology.

Dr. Mathew L Thakur

Professor of Radiology,
Radiation Oncology & Urology,
Thomas Jefferson University
View More

Dr. Eric Wickstrom

Professor of Biochemistry &
Molecular Biology,
Thomas Jefferson University
View More

Corporate

Tibor Gajdics

President, CEO & Chairman
KOP Therapeutics
View More

Mark Redcliffe

VP & Director
KOP Therapeutics
View More

Marco Strub

Director
KOP Therapeutics
View More

Leigh Berryman

KOP Therapeutics
Executive Fractional Director of Development
View More

Joyce Heinzerling Davis

Director
KOP Therapeutics
View More

Jakson Inwentash

Chief Business Development
Officer & Director
KOP Therapeutics
View More

Aziz-Ur Rehman

Chief Financial Controller
KOP Therapeutics
View More

Sylvie Quenneville, B.Soc.Sc.

VP of Strategic Development & Corporate Affairs
KOP Therapeutics
View More

Advisory Board

Eric J. Mathur

KOP Therapeutics
Scientific Advisory Board Member
View More

Dr. Emma S. Guns

KOP Therapeutics
Past Scientific Advisory Board Member
View More

Jeff Howlett, BSc(Econ.)

KOP Therapeutics
Advisory Board Member
Head of Research
View More

Legal

Brian William Karam

In-House Counsel
KOP Therapeutics
View More

SECURITIES LAWYER: PAUL FANG

Fang and Associates Barristers & Solicitors
Suite 1400, 1125 Howe Street, Vancouver, BC V6Z 2K8
T: 604.256.9900
E: pmf@falawyers.ca

SECURITIES ATTORNEY: PAUL FANG

Fang Law Corporation
1400-1125 Howe St. Vancouver, British Columbia V6Z 2K8
T: 604-256-9900
F: 604-688-6995
E: pmf@falawyers.ca

IP LAWYER: THEODORE SUM, PARTNER SMART & BIGGAR/FETHERSTONHAUGH

2300-1055 WEST GEORGIA STREET, VANCOUVER, BC V6E 3P3
T: 604.682.7780
E: TWSUM@SMART-BIGGAR.CA

KOP is Aligned with

KOP-101

KOP’s AI-Validated Cancer Treatment Platform

KOP’s, AI-validated KOP-101 has two primary components:
1 – Drives KOP-101 to only cancer cells and cancer stem cells and
2 – Enters the Cancer Cell and Cancer Stem Cell through the process of Endocytosis, and Silences a previously unrecognized mRNA gene thereby preventing cancer cell and cancer stem cell nourishment, resulting in cancer cell and cancer stem cell death within days with negligible side effects.
3 – KOP-101 Drug Silences the Cancer.

Our Approach

KOP THERAPEUTICS' NOVEL AI-ENABLED DRUG DESIGN PLATFORM

KOP Therapeutics’ AI-enabled drug design is composed of two active components: One that drives the drug selectively to the cancer cells and the second genetic component that blocks the bad copies of the mutated cancer gene inside the cells, preventing cancer growth and rendering the cells dormant thus causing the cell to die. While doing so, the KOP drug does not attack normal cells and is expected to kill the cells that are resistant to current therapies where cancer can come back.

KOP-101 MECHANISM OF ACTION

STEP 1
DRUG BINDS AND ENTERS THE CELL
KOP Therapeutics’ unique and novel AI-enabled drug design platform has two active components. They work in tandem, killing malignant cells and sparing the normal healthy cells.
STEP 2
KOP-101 Drug Kills malignant cells and spares the normal cells.
STEP 3
KOP-101 Drug Silences the Cancer

PIPELINE

The KOP Drug Platform is designed to treat cancer by targeting, blocking and silencing particular cancer genes with minimal side effects and preventing recurrences.

We anticipate the KOP-101 P Drug to successfully target many more tumor types but if necessary can streamline more drugs as stated below.

Charitable Giving

DISCOVER THE POWER OF PHILANTHROPY AND SUPPORT OUR RESEARCH WITH THOMAS JEFFERSON UNIVERSITY — SIDNEY KIMMEL CANCER CENTRE

“KOP Therapeutics’ strategic alliance and partnership with TJU & SKCC redefines tomorrow’s cancer care with world renowned scientific experts, Dr. Mathew Thakur and Dr. Eric Wickstrom revolutionary scientific breakthroughs further developed into novel therapies. Your transformational gift goes directly to Thomas Jefferson University and applied to Dr. Thakur and Dr. Wickstrom Research Fund.

Learn More

Donate

FaceBook

Contact Us

To learn more about the KOP Therapeutics Drug Platform, please complete this form and get involved in an extraordinary opportunity and scientific discovery.

KOP Therapeutics Corp.
501-815 Hornby Street
Vancouver, BC V6Z 2E6,
Canada

DISCLAIMER

The information contained in this presentation is in summary form only, is not intended to be complete and may contain inadvertent or unintentional errors. No representation, warranty or guarantee, expressed or implied, is made as to the fairness, accuracy or completeness of information contained herein, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, results or statements in relation to future matters contained in this presentation. This presentation does not constitute an offer to sell or the solicitation of an offer to buy any security and is not intended to be relied upon as advice to investors or potential investors. KOP is not liable to any recipient or third party for the use of or reliance on the information contained in this presentation.

This communication contains forward-looking statements, which relate to future events  or future performance, that are neither promises nor guarantees and are subject to numerous risks and uncertainties that may cause future results to differ materially from those expected and does not constitute an offer to sell or a solicitation of an offer to buy any securities. KOP’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of a U.S. person (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available.

Also, this communication is intended for the sole use of the addressee(s) and may contain confidential, personal and/or privileged information. Unless you are the intended, recipient, we ask that you do not retain, disclose, distribute, or take action relying on any information contained herein, and that you please alert us immediately of the erroneous delivery by return e-mail. Any communication received in error, or subsequent reply should be deleted or destroyed. Thank you for your cooperation.

COPYRIGHT AND TRADEMARK

The information in this presentation ( including certain names, graphics, logos, icons, designs, words, titles or phrases) is protected by copyright and other laws and may not be copied, reproduced, modified, uploaded, posted, transmitted, or distributed in any way without KOP’ s prior written approval. Any unauthorized downloading, re-transmission, re-publication or other copying or modification of trademarks and/or the contents herein is strictly prohibited
logo

KOP Therapeutics, 501-815 Hornby Street Vancouver, BC V6Z 2E6, Canada

Leigh Berryman

Leigh Berryman

KOP Therapeutics Executive Fractional Director of Development
As a Partner in L2 Consulting, Leigh Berryman is a serial Chief Executive Officer who has provided leadership to companies in Europe, North America and Asia. Trained as a toxicologist, he has been involved and directed drug development programs for over 35 years and has led or contributed to over 300 IND applications and first-in-man programs across Europe and North America. In particular, he was a lead scientist for one of the pioneering recombinant products, rhEPO. From this scientific foundation, Leigh progressed into executive management in the mid-90’s, founding and ultimately taking public (Toronto Stock eXchange), his own company LAB Research Inc. (“LAB”). Thereafter he provided turnaround leadership to Ricerca LLC (in Ohio), a 300+ person

company, doubling revenues and enabling capital investment for growth and M&A activity over a 2 year period. He stepped into another CEO role in Singapore (Maccine Pte. Ltd.) and, over a 6-year period, brought the company to profitability. Since 2014, he has worked with early stage companies in advisory and consulting roles to design development programs with a focus on cost and timing to enable evaluation of risk and return on required investment capital.

E.L. Berryman B.Sc.(Hons.), MRB. CBiol. RQAP-GLP, Reg. Toxicologist
Sylvie 2

Sylvie Quenneville, B.Soc.Sc.

VP of Strategic Development & Corporate Affairs
KOP Therapeutics
As Vice President of Strategic Development & Corporate Affairs at KOP Therapeutics, Sylvie Quenneville leads corporate strategy, ecosystem engagement, and government relations to support the company’s growth in oncology, specifically in the mRNA sector.

With deep experience in public-private partnerships and strategic planning, she plays a pivotal role in advancing KOP’s mission through cross-sector collaboration, funding initiatives, and integration into Quebec’s life sciences ecosystem. Having been with KOP since it’s inception in 2019, working closely alongside the founding Director, President & CEO, and the founders of the technology, her leadership bridges innovation, policy, and impact. With over 25 years of experience in business, finance and biotech, Sylvie is a highly analytical and results-driven professional who excels at analyzing market trends, understanding client needs, and delivering strategic solution. Her expertise lies in corporate affairs managing complex tasks, complemented by a detail-oriented and proactive approach that thrives in dynamic, fast-paced environments.
Aziz-Ur-5

Aziz-Ur Rehman

Chief Financial Controller
Aziz Rehman serves as the Financial Controller, leading with remarkable expertise and a commitment to financial excellence. Holding CPA and CGA certifications in Canada, ACCA credentials from the UK, and a Bachelor of General Studies from Athabasca University, Aziz is known for his precision, innovative mindset, and dedication to achieving superior results. He excels in transforming financial reporting, compliance, and strategic planning into competitive advantages, delivering meticulous financial statements and Management Discussion and Analysis reports that meet the highest IFRS standards.

A trusted advisor to auditors, tax experts, and legal teams, Aziz’s leadership consistently drives growth and positions the organization for ongoing success. With deep expertise in cash management, loan negotiations, cost optimization, and tax guidance, Aziz ensures our business thrives, helping navigate complex financial environments with ease. His comprehensive knowledge of CRA interactions and strategic thinking makes him a key asset in overcoming challenges and seizing opportunities for growth.
Brian-William-Karam

Brian William Karam

In-House Counsel KOP Therapeutics

Mr. Brian William Karam has practiced law in Ottawa, Canada since 1973. From 1995 to 2015, the focus of his legal practice was large multi-family mortgage work, a portion of which involved difficult to structure social housing initiatives. Until the mid-1980’s he worked with First Nation artists and craft-persons. Thereafter he served for 5 years as President of CODE, a Canadian NGO, working to enhance literacy and education in the third world. He also developed the first fibre-to-the-door subdivision in the world, with formal live/work zoning that involved housing construction beginning 2005. He holds the USA and Canadian Patent on infrastructure for any Smart Building. He is also involved in the Hotel/Restaurant business and a longtime member of the charitable Dewaan Foundation. His philanthropy has focused on local hospitals and assisting immigrants to Canada to establish family operated businesses. Such latter efforts were formally recognized by a plaque presented to him by the Embassy of Lebanon. He has among other honours, received The Queen’s Diamond Jubilee Medal and the Sovereign’s Medal for Volunteerism and the United Way Community Builder Award.

Eric-J-Mathur

Eric J. Mathur

Scientific Advisory Board Member
KOP Therapeutics

Eric Mathur currently serves Chief Executive Officer of Diomics and is focused on development and commercialization of a novel polymer with broad applications in diagnostics, forensics, nutraceutical and drug delivery marketplaces. His expertise and knowledge traverses’ genome sciences, molecular biology, environmental microbiology, plant-microbe interactions, metagenomics, enzyme & drug discovery, plant domestication and applied biotechnology.

Mathur’s career spans over 40 years in basic and applied biotechnology with focus on translational science. Eric entered the San Diego biotechnology arena early, in 1983 as founder of Stratagene, where he discovered and commercialized Pfu DNA polymerase, which is still a mainstay enzyme used in the PCR industry. After a nine years’ tenure, Mathur was recruited to become the first employee of Diversa Corporation, which later achieved the largest biotech IPO of the time, raising $200MM in 2001. At Diversa, Eric managed a large scientific team and multiple corporate collaborations with industrial partners including Syngenta, Dow Chemical and BASF. Following 14 years with Diversa, Mathur was recruited to start Craig Venter’s company, Synthetic Genomics where he led research efforts in microbial enhanced hydrocarbon recovery sponsored by BP; he also spearheaded the genome sequencing and annotation the oil palm genome for Genting Berhad; and established a platform for plant growth promoting bacteria which led to the spinout, Agradis and subsequent Monsanto acquisition.

Eric’s interests then turned to plant genomics and crop domestication; he worked as Chief Science Officer for several companies including Yulex Corporation and SG Biofuels, GreenKiss NY and Cultivation Technologies Inc., and most recently Tilt Holdings, where he applied modern genomic tools and plant molecular breeding methods to accelerate plant productivity. His work culminated in dramatic yield improvements in these two sustainable crops, Guayule for natural rubber production and Jatropha for biodiesel. In addition, Mathur’s team has made significant advances in Cannabis & Hemp and continues plant improvement activities with a number of organizations.

Eric Mathur is an internationally recognized speaker who authored over 50 peer-reviewed publications and is named inventor on 100+ issued patents. Eric’s passion lies in leveraging genome-based technologies to develop nutrient dense foods and therapeutic medicinals; Mathur is also an ardent supporter of sustainable agricultural and does his part to help secure global food & energy security, while minimizing the impact on our fragile environment.

Jakson Inwentash

Jakson Inwentash

Chief Business Development Officer & Director
KOP Therapeutics

Mr. Inwentash is a director and VP of Investments at ThreeD Capital, where he focuses on identifying, researching, and meeting with early stage companies in various disruptive industries. He is also a registered Dealer Representative and has a successful track record of raising capital in industries such as mining, battery recycling, organic food, high performance computing, biotechnology and blockchain. Mr. Inwentash has significant capital markets experience; he is an advisor and board member of several private and publicly listed companies.

Female portrait icon as avatar or profile picture

Catherine Mann

KOP Therapeutics
Advisory Board Member

Jeff Howlett photo

Jeff Howlett, BSc(Econ.)

KOP Therapeutics
Advisory Board Member
Head of Research

Jeff Howlett, BSC(Econ.) University of Pennsylvania

Mr. Howlett has a 35+ year history in research-based finance and independent research. His experience spans corporate finance, mergers and acquisitions, due diligence assignments, business and strategic planning, , and royalty financing. Industry focus has primarily included a broad range of resource-related and technology sectors.
emma-guns

Dr. Emma S. Guns

KOP Therapeutics
Past Scientific Advisory Board Member
Dr Emma (Tomlinson) Guns, graduated from the University of Liverpool in Pharmacology/Chemistry and completed a PhD in steroid drug metabolism (1997). During the past two decades she built and sustained operation of the Analytical Mass Spectrometry Core facility at The Vancouver Prostate Centre to facilitate drug discovery research at the centre and her research lab as well as countless other scientists working in cancer research. Former member of the Faculty of Medicine at The University of British Columbia, Vancouver, Canada. As faculty in the Department of Urologic Sciences, she was a Senior Research Scientist at The Vancouver Prostate Centre having secured CFI funding to create a Pharmacology Core there in 2003. Within the past 5 years Dr. Guns sat on the clinical research ethics board (CREB) for UBC and VGH (Vancouver General Hospital) as well as numerous grant review panels for amongst others, the Canadian Institutes for Health Research (CIHR), providing expertise in the pre-clinical evaluation of drugs for use in prostate and breast cancer. She has published more that 100 peer reviewed articles and secured millions of dollars in research funding.
joyce-davis

Joyce Heinzerling Davis

Director
New York University School of Law
KOP Therapeutics

Joyce Heinzerling Davis has extensive professional experience in the fields of law and corporate governance. In addition to KOP’s Board of Directors, Ms. Heinzerling Davis currently serves on the board of directors of the Value Line Funds, a $5B US mutual fund family.

Ms. Heinzerling Davis previously served from April 2009 – December 2020 as Managing Member of Meridian Fund Advisers LLC, a US regulatory consulting firm engaged in creative problem-solving and strategic thinking for US private equity funds and US and non-US hedge funds. Some of Meridian’s largest projects included creating private company board governance protocols and customized regulatory infrastructures. Prior thereto, from April 2000 to April 2008, Ms. Heinzerling Davis was the General Counsel and Co-Chief Operating Officer of Archery Capital LLC, a NY-based fund-of-funds. Her responsibilities also included co-managing Meridian’s private venture capital fund. Ms. Heinzerling started her career as a lawyer working as an in-house counsel for the investment fund groups at Ladenburg Thalmann and Lazard Freres, after which she spent fourteen years working in private practice for private equity, hedge fund, and venture capital funds at two private law firms – Kramer Levin and Shearman & Sterling. 

Ms. Heinzerling Davis is a graduate of NYU’s Graduate School of Law and has served on other corporate and non-profit boards and advisory boards. Ms. Heinzerling Davis frequently served as a panelist at industry conferences covering topics including regulatory developments and best practices for fund governance.
marco-strub

Marco Strub

Director
KOP Therapeutics
Marco Strub, Masters Degree University of St.Gallen, Switzerland. Extensive experience in the private sector.

Marco Strub has over 25 years of experience as an entrepreneur and executive in the financial services and consulting sectors. Since March 2003, Mr. Strub has been the Principal and Chief Executive Officer of Sircon AG, a portfolio management company based in Zurich, Switzerland. Prior to this, Mr. Strub served as a Partner of Exulta AG from 1997 to 2003. He has been an Independent Director of numerous private and publicly listed companies, including Triumph Gold Corp and ZincX Resources Corp, listed on the TSX Venture Exchange. Mr. Strub received a Master of Arts degree from the University of St. Gallen, Switzerland in 1982. and as a principal of Sircon AG, A consulting and investment research firm in Zurich, Switzerland. On Board of various publicly listed companies and acting as an independent director of Triumph Gold Corp. and ZincX.
mark-redcliffe

Mark Redcliffe

VP & Director
KOP Therapeutics
MBA and CPA, CMA designation with 21 years experience in securities sector. Established ties with Canadian and International private equity firms, investment dealers, family offices and high net worth individuals. Successfully overseen more than 500 placements, initial public offerings and cross-border advisory mandates.
ian-mann

Ian Mann

Executive Chairman & Director
KOP Therapeutics

Bachelor of Arts, Honors Business Administration degree from University of Western Ontario in London, Canada. 2003-2019 President of Meridian Fund Managers Ltd, BVI registered fund manager with two alternative investment funds primarily investing in mining and oil and gas companies. Since 1997, served as non-executive director of three Canadian Exchange listed mining and oil companies, now merged into other entities and Grand Columbia Gold Ltd. Director of two AIM listed companies , President and CEO Squire Mining Ltd, 2011-2017, a CSE-listed early stage company.
tibor-gajdics

Tibor Gajdics

President, CEO & Chairman
KOP Therapeutics

With over 40 years experience as an investment professional, Mr. Gajdics is a successful entrepreneur and founding director of several start-ups.  Tibor specializes in building shareholder value by taking early stage companies through to a thriving business. Improving lives through the advancement of medicine is demonstrated by his unflagging commitment to the commercialization of the KOP-101 Drug and providing new and innovative cancer treatment solutions. 

As the Founder, CEO & President of KOP Therapeutics, Tibor and his team successfully negotiated the acquisition of the exclusive worldwide license of the KOP Drug from Thomas Jefferson University in Philadelphia, in October 2019.  Jefferson Health is recognized for its record of Excellence in Healthcare with TJU Hospitals ranked among the top 10 in the world. Licensing technology from TJU provided KOP Therapeutics access to world experts in cancer biology, performing cutting edge research, as well as gaining early access to the technology at a significantly lower price.  Tibor has continued to expand the KOP Team with key investors, and world renowned researchers.

This team has enabled KOP Therapeutics, to advance the research from in- vitro validation to in-vivo validation with the Investigational New Drug Application FDA submission planned for 2024.

eric-wickstrom

Dr. Eric Wickstrom

Professor of Biochemistry &
Molecular Biology,
Thomas Jefferson University
Eric Wickstrom, Ph.D., and his coworkers design genetic therapy agents to block cancer gene activity and restore immune cell attacks on cancer cells. Prof. Wickstrom and his coworkers also design nuclear medicine genetic probes to visualize the activity of cancer genes. Eric Wickstrom is a Professor of Biochemistry and Molecular Biology in the Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, Pennsylvania, USA. Prof. Wickstrom earned a Bachelor of Sciences with Honor in Biology from the California Institute of Technology, in Pasadena, California, USA, and a Ph.D. in Chemistry from the University of California, Berkeley, California, USA. Prof. Wickstrom has published 133 research papers, 230 research abstracts, 48 reviews and chapters, 7 patents, and 2 books, on molecular design, nucleic acid structure, gene function, mRNA translation, protein structure, and cell biology. Federal and private organizations have awarded Prof. Wickstrom over US$18 million to support his investigations.
Mathew_Thakur

Dr. Mathew L Thakur

Professor of Radiology,
Radiation Oncology & Urology,
Thomas Jefferson University
Dr. Mathew Thakur is a Professor of Radiology, Radiation and Urology at Thomas Jefferson University in Philadelphia, USA. He is an active member of SKCC and the director of the Laboratoires of Radiopharmaceutical Research and Molecular Imaging. He obtained his MS and PhD degrees from the University London, England. He was a member of the scientific staff, Grade 1 at the Medical Research Council, Hammersmith Hospital, London, England and a Visiting professor at Washington University, St. Louis, MO. Before arriving at TJU, he then was Assoc. Prof. of Radiology at Yale University, Newhaven, CT. and Research Assoc. at Brookhaven National Laboratory in Long Island, NY.

The major thrust of his research is to develop radiopharmaceuticals for diagnostic and therapeutic applications of life-threatening diseases. He has published more than 500 original articles, review papers, book chapters, abstracts, and editorials. He has also published 4 books and translated his basic research into translational clinical applications. He has given more then 500 invited and named presentations in the USA and abroad, in academic institutions, industries, and at national and and international scientific gatherings. He holds 30 active and pending patents and serves on the editorial board for 24 journals. As a PI and a Co-PI, his research has always been funded by federal, foundational, and industrial grants. Currently, I hold three eINDs from the US FDA to perform translational clinical research. His extensive contributions to the field of nuclear medicine and molecular imaging are well recognized by his peers, for which he has received 13 national and international awards, including the Society of Nuclear Medicine’s highest honor, the Benedict Cassen award. He is a fellow of five prestigious professional organizations and has been elected as President of three international societies, including the Society of Nuclear Medicine and Molecular Imaging. During his career he has collaborated with many national and international institutions and been a close associate of Dr. Wickstrom for more than two decades.